Nonablative hematopoietic cell transplantation (HCT) is becoming a preferred treatment for those recipients in whom the potential toxicity risk of standard ablative allogeneic therapy may be unacceptable. Graft-versusmalignancy effects may be generated against epithelial malignancies which are similar to the graft-versus-leukemia activity that is well documented in human hematological malignancies. Renal 
taneous regression which typically follows nephrectomy. 3, 4 Some metastases initially progress slowly, if at all, while others progress rapidly, making treatment difficult. Treatment for metastatic renal cancer is not usually successful and the median prognosis for survival despite added cytokine therapy is 10 months.
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Therapy and survival
Standard chemotherapeutic and hormonal approaches are generally unsuccessful. 6, 7 Immunomodulator therapies utilizing interferon have been used with some success in patients with metastatic RCC. [8] [9] [10] [11] [12] Nephrectomy, followed by interferon alfa-2b, accomplishes longer survival among patients with metastatic RCC than does interferon therapy alone. 9 IL-2 is FDA-approved and considered standard therapy for metastatic renal cell carcinoma; however, many patients are not eligible because of poor performance status or concurrent organ dysfunction. Approximately 15-20% of patients have an objective response to therapy, and although the complete response (CR) rate is 5-7%, approximately 80% of these complete responders will experience response duration of greater than 2 years. [13] [14] [15] [16] Toxicity of high-dose IL-2 therapy is significant, although the treatment-related mortality is less than 1%. 14 The toxicities include hypotension requiring pressors, major organ failure, myocardial infarction and potentially fatal systemic capillary leak. Fisher reported that the median response duration of the original cohort of 255 RCC patients treated with high-dose IL-2 was 54 months (range, 3-131 months). 17, 18 The median duration for complete responders was not reached, but was greater than or equal to 80 months (range, 7-131 months). Median survival for all 255 patients was 16.3 months, with 10-20% estimated to be alive 5-10 years post treatment. Regimens combining IL-2 and other agents appear to have similar response rates compared to IL-2 alone.
12,15 Low-to moderate-dose parenteral IL-2 may be associated with similar response rates and less toxicity. 19, 20 However, a phase III study of the Cytokine Working Group found that treatment with high-dose IL-2 demonstrated a significantly higher objective response rate than did treatment with low-dose IL-2/interferon. 21 Conventional treatment options are summarized in Table 1 . Immunological aspects of renal cell carcinoma
Defined tumor antigens in renal cell cancer
The core components of cell-mediated immunity are peptide-specific T lymphocytes, which recognize antigens carried in the cleft of the MHC molecule of the antigen presenting cell. This allows the T cell to distinguish self from non-self and target from non-target. Renal cell-specific cytotoxic T cells exist; however, infiltrating T cells derived from tumors thus far studied proliferate poorly in response to antigenic stimulation. 22, 23 Cytotoxic T lymphocyte (CTL) clones reactive against autologous RCC tumor cell lines have identified the specific peptide antigens on RCC which are recognized by T cells, leading to lysis of the tumor cell. [24] [25] [26] [27] T cell clones can also be produced utilizing RCC cells transduced with cDNA encoding the costimulatory molecule B 7.1, or T cell cytokines interleukin (IL)-2, IL-7 and IL-12. [28] [29] [30] These data confirm the existence of RCC-specific CTL in some patients with RCC, and demonstrate the existence of peptide antigens on RCC cells which permit T lymphocyte recognition.
Clinical studies of adoptive immunotherapy in RCC
The success of cytokine therapy prompted investigation of specific cellular adoptive therapy for the treatment of RCC which delivers T cells directly (adoptive transfer), or by priming with vaccination. Early clinical trials demonstrated objective responses. [31] [32] [33] However, treatment in a large randomized study with tumor-infiltrating lymphocytes (TILs) in RCC administered with IL-2 compared to IL-2 alone failed to demonstrate additional benefit, although the target number of TILs administered was not reached, and the trial must be considered inconclusive. 34 Active vaccination may be combined with adoptive cellular transfer. Primed lymphocytes cultured from autologous vaccine-draining lymph nodes and systemic IL-2 were concomitantly given to patients with melanoma and RCC and induced objective responses. [35] [36] [37] One patient with RCC was also noted to have an oligoclonal T lymphocytic infiltration in a responding pulmonary metastasis. 38, 39 Dendritic cells (DCs) are antigen presenting cells that stimulate T cells to respond to appropriate targets. These cells, when exposed to tumor cell lysates or antigens, 'present' antigen even when the tumor antigens are not fully characterized. 40 Preclinical studies demonstrate potent anti-tumor activity in animal models. [40] [41] [42] The initial clinical trial of a DC-based vaccine was conducted in patients with B cell lymphoma who had failed conventional chemotherapy; DCs had been pulsed with autologous antigen obtained from tumor biopsies. Three of 10 patients experienced a CR, and one a partial response (PR). CRs lasted 40+, 44+ and 62+ months. One patient experienced reversion of a BCL-2 translocation-positive marrow to normal. 43 DC-based clinical trials are underway or completed in patients with multiple myeloma, prostate carcinoma and melanoma. [44] [45] [46] Allogeneic DCs electrofused to recipient tumor were given to patients with metastatic RCC. Seventeen subjects received two subcutaneous injections, separated by 6 weeks. Patients experienced minimal to moderate toxicity, including injection site pain, swelling and fevers. There were four complete and two partial responses. Eleven of 17 patients developed tumor-specific delayed-type hypersensitivity, including 5/6 responders. 47 This body of basic, pre-clinical and clinical data suggests that immunological mechanisms are involved in defense against at least some types of RCC, and suggest a rationale for HCT as adoptive immunotherapy for RCC (see Table 2 ).
Hematopoietic cell transplantation
Graft-versus-host disease (GVHD), an alloimmune attack against host tissues mounted by donor T cells, is the most important toxicity of allogeneic hematopoietic cell transplantation (HCT). 48, 49 Clinical observations support the existence of graft-versus-malignancy (GVM) activity; this is demonstrated directly in humans by the infusion of donor lymphocytes, which induce remissions in patients with relapsed chronic myelogenous leukemia. GVM denotes direction of this activity against leukemic and/or solid organ malignant cells. [50] [51] [52] [53] [54] [55] [56] [57] [58] Minor histocompatibility antigenic differences between donor lymphocytes and recipient malignant cells may be an important factor in the production of GVM activity. 
GVHD, GVM and mixed chimerism
GVHD is associated with GVM; unfortunately, GVHD is also a morbid or fatal transplant complication. Multiple strategies aim to 'separate' GVM activity from clinical GVHD. Whether this goal is achievable may depend on whether target antigens or effector cells that mediate GVM differ from those that cause GVHD. One method for isolating the GVM effect is the creation of mixed lymphoid chimeras. The term chimerism describes the presence of allogeneic hematopoietic or lymphoid cells in a transplant recipient. The lymphohematopoietic organ is of donor origin, and resides amongst recipient tissues. HCT recipients are considered fully chimeric when all hematopoietic cells and lymphoid cells are derived from the donor. The term 'mixed chimerism' describes a state in which recipient hematopoietic and/or lymphoid cells persist together with donor cells after HCT.
Sykes et al demonstrated that murine GVM activity is induced in murine mixed chimeras without clinical GVHD. Lethally irradiated mice reconstituted with T cell-depleted (TCD) allogeneic and non-TCD autologous bone marrow became tolerant to MHC-disparate donor alloantigens and yet were able to respond immunologically to third-party antigens. 59, 60 The mechanism of tolerance appears to depend on donor dendritic-like cells that express MHC class II in the recipient thymus, resulting in the deletion of host-reactive recipient T cell clones. 61 Pelot confirmed that murine mixed chimeras produced by nonablative conditioning induce a lymphohematopoietic GVH reaction without clinical GVHD. 62 
Mixed chimerism in human transplantation
Studies of allogeneic transplantation in humans for nonmalignant disease predict that a state of mixed chimerism reduces the frequency and severity of GVHD when compared to fully chimeric reconstitution. Some patients with aplastic anemia who receive standard allotransplants experience mixed engraftment; these patients experience less GVHD than do those who engraft 100% donor cells. 64 Mixed chimerism is associated with beneficial outcomes in other nonmalignant diseases, including beta-thalassemia, sickle cell disease, mucopolysaccharidosis and severe combined immunodeficiency disease. [65] [66] [67] [68] [69] Mixed chimerism was first demonstrated in cancer patients treated with allogeneic BMT for leukemia. 70 Infusions of donor lymphocytes were later shown to convert mixed to full donor chimerism. This permitted an anti-tumor effect, which appears to be Bone Marrow Transplantation most potent in patients with CML, chronic lymphocytic leukemia and multiple myeloma.
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Nonablative HCT in humans
Sentinel nonablative HCT studies in humans demonstrated decreased early transplant-related morbidity, even in older patients with late stage hematologic malignancies. These transplants are characterized by high rates of engraftment and evidence for the presence of allogeneic anti-tumor effects; however, most patients experience full donor chimerism, similar to myeloablated recipients; relatively few experienced prolonged periods of mixed chimerism. [74] [75] [76] [77] [78] [79] [80] A multitude of subsequent clinical investigations concerned the use of modified nonablative conditioning regimens in patients with a variety of hematological malignancies, nonmalignant hematological disorders and solid tumors. The following conclusions can be made regarding clinical nonablative compared to myeloablative HCT in humans: (1) engraftment is regularly achieved; (2) mucositis rates and severity are decreased; (3) the incidence of veno-occlusive liver disease is reduced; (4) the establishment of stable long-term mixed chimeras is infrequent; (5) acute and chronic GVHD continue to contribute to significant morbidity and mortality; (6) post-transplant infections in the early transplant period are reduced, but infection risk persists in the longer term, especially in those who experience GVHD; (7) durability of anticancer effects is unknown; (8) disease-specific conditioning and GVHD prophylaxis regimens are not standardized. Reviews have been published.
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Nonablative transplantation in renal cell transplantation
Childs and Barrett at NHLBI pioneered the use of nonablative allogeneic transplantation for the treatment of metastatic RCC. The initial case was a 50-year-old male with stage III renal cell (clear cell) who developed interferon alpha 2b-resistant pulmonary metastases 7 months following left nephrectomy. The patient received a matched related, non-depleted, G-CSF-mobilized peripheral blood stem cell product containing 9.1 ϫ 10 6 CD34 + cells/kg and 4.2 ϫ 10 3 CD3 + T cells/kg, following conditioning with fludarabine and cyclophosphamide. GVH prophylaxis consisted of cyclosporin A (CsA). Engraftment occurred swiftly; neutrophil recovery occurred by day +10; platelet nadir was 40 000/mm 3 . T cell chimerism was 50% by day +30 and 100% by day +100. Cyclosporine was weaned and stopped by day +45. Donor myeloid and CD34
+ progenitor engraftment were slower, reaching 100% by day +100, consistent with a GVH hematopoietic effect. The patient experienced transient grade I acute GVHD of the skin on day +60 and limited chronic skin GVHD, which responded to CsA resumption and low-dose alternate day glucocorticosteroids. Chest CT revealed no change at day +30, but reduction in metastatic disease detectable by day +63 and complete resolution by day +110; the patient remained in remission for at least 15 months after transplantation. 94 
Table 3
Clinical studies in humans of HCT for the treatment of renal cell carcinoma This result prompted the execution of a pilot study of 19 patients who were similarly treated. The nonablative preparative regimen was followed by an infusion of donor lymphocytes to some patients with mixed T cell chimerism or disease progression. Patients with no response received up to three infusions of donor lymphocytes. Nine of the 19 patients were living 287 to 831 days after transplantation (median follow-up, 402 days). Two died of transplantrelated causes, eight from progressive disease. Ten patients experienced metastatic disease regression; three had a complete response and seven a partial response. The patients who had a complete response remained in remission 27, 25 and 16 months after transplantation. Regression of metastases was delayed, occurring a median of 129 days after transplantation, and appeared to follow the withdrawal of cyclosporine and establishment of complete donor T cell chimerism. These results are consistent with a GVM effect. The authors concluded that this approach could lead to prolonged remissions in some patients with metastatic RCC who have had no response to conventional immunotherapy. 95 A pilot study by an Italian team evaluated the engraftment and toxicity of reduced-intensity preparations in patients with refractory malignancies. Seven patients with metastatic RCC received mobilized peripheral blood progenitor grafts from matched related donors following conditioning with fludarabine and cyclophosphamide, with cyclosporine/methotrexate GVHD prophylaxis. Six of seven (85%) engrafted. Five patients (70%) experienced уgrade 3 toxicity. It is noteworthy that no patients experienced acute GVHD and all progressed and died by day +80, (mean, day +42). 96 Rini et al recently reported the University of Chicago experience that consisted of 15 patients with metastatic RCC who underwent matched sibling nonablative allogeneic transplant following conditioning with a fludarabine/cyclophosphamide-based regimen. 97 Three of the first four patients failed to engraft and the fludarabine dose was intensified. Eleven of 12 patients then engrafted and were followed for over 180 days. Acute GVHD occurred in two patients, chronic GVHD occurred in six and there were four transplant-related deaths. Four (33%) partial responses were observed. It is important to note that the 15 transplanted patients were chosen from a cohort of 284 patients, 84 of whom had a matched related donor. 97 Bregni et al investigated the feasibility and toxicity of nonablative therapy using thiotepa, fludarabine and cyclophosphamide in seven patients with RCC (and eight patients with breast cancer). Donor lymphocyte infusions and/or interferon were given in the post-transplant period for patients showing no tumor response and no GVHD. All patients with RCC engrafted. Partial remissions were seen in four of seven (56%) patients following post-transplant immune suppression withdrawl and/or after DLI and/or interferon.
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Conclusions
Nonablative HCT is becoming a preferred treatment for indications where the toxicity of standard ablative allogeneic therapy is unacceptable. Factors to consider include susceptibility of the underlying malignancy to GVM, previous response to chemotherapy, extent of residual disease, donor availability and prospects for alternative investigational therapies. GVHD and disease recurrence remain the major obstacles to success. Childs et al have demonstrated that engraftment is regularly achieved in patients with RCC transplanted with nonablative conditioning using matched related donors. 95 Preliminary information suggests that mixed chimerism does not appear to be stable over time; most patients will progress to full donor chimerism and a small minority experience graft rejection. Full chimerism precedes effective adoptive antitumor responses. This implies that benefits of mixed chimerism in reducing severe GVHD may be realized only by compromising GVM potency. A significant portion of patients, however, experiences antitumor responses without DLI. It is of paramount importance that the mechanism of antitumor activity is elucidated during future clinical trials for RCC.
Despite the rapid evolution of cytokine-based therapy, clinical investigations indicate that the survival benefits are not optimal; alternative strategies should be explored.
Further clinical investigation in nonablative transplantation will expose patients to a serious but treatable iatrogenic complications. This risk seems justifiable for patients who have not responded to cytokine-based therapy. Conversely, excluding cytokine responders may lead to the accrual of transplant candidates who are less likely to respond to allogeneic adoptive immunotherapy. The consequences of severe GVHD, nonetheless, are more significant than those adverse effects that are generally seen with cytokinebased therapy.
Additional studies should build on the promising results that were seen by the NCI group and others. One could question the need to deviate substantially from the NCI conditioning regimen for the following reasons: (1) high rates of engraftment with the Childs regimen; (2) low rates of mucositis; (3) evidence for efficacy and (4) lack of chemosensitivity of RCC. It could be argued that adjustments with the next generation of studies should aim to prevent severe GVHD. This could be attempted by graft engineering, ie CD8
+ cell depletion, as per Nimer et al. 99 Other strategies to reduce GVHD risk include intensification of the peritransplant anti-lymphocyte activity, alteration of donor cell dose, and requiring ABO matching as an inclusion. Because the panacea of isolating GVM from clinical GVHD is yet to be achieved in humans, the identification of relevant tumor antigens should be a priority. Identification of such antigens may permit ex vivo expansion of tumor specific cytotoxic T lymphocytes and allow provision of an allogeneic antitumor effect without significant GVHD. CALGB and ECOG have initiated a cooperative phase II trial of nonablative matched related donor allogeneic stem cell transplantation in patients with metastatic RCC. Eligible patients must have measurable metastatic clear cell or papillary RCC, and must have received prior therapy with either IL-2 or IFN gamma. Patients are eligible who are less than 61 years of age, with an ECOG performance status of less than or equal to 1. They must have a 6/6 matched related donor by serological typing. Nephrectomy is not required. Tumor tissue samples will be used with peripheral blood mononuclear cells obtained from treated patients in studies that will attempt to define T cell repertoire and target T cell antigens.
